FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291939922> ?p ?o ?g. }

• W4291939922 abstract "Abstract Background Accumulating evidence supports the role of monocytes and neutrophils in radiographic axSpA (r-axSpA). Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor for both leukocyte lineages and a pro-inflammatory cytokine activating myeloid cells and promoting osteoclastogenesis. It acts through the JAK-STAT pathway. We measured serum GM-CSF and markers of bone metabolism in patients with r-axSpA before and after anti-TNF treatment. Methods Patients with active r-axSpA despite treatment with NSAIDs, all eligible for treatment with a biologic agent, were recruited. Healthy donors were sampled as controls. Serum was collected before (baseline) and after 4–6 months (follow-up) of anti-TNF treatment and the following molecules were measured with ELISA: GM-CSF, sclerostin (SOST), and dickkopf-1 (Dkk-1). Results Twelve r-axSpA patients (7 males, 5 females, median age 37 years) with a median disease duration of 1 year and 16 age- and sex-matched controls were included. At baseline, patients had mean BASDAI 6.3±2 and ASDAS 3.2±0.7, which decreased to 4.1±1.7 and 2.2±0.6 at follow-up, respectively. At baseline, r-axSpA patients had significantly higher mean serum levels of GM-CSF (150 vs 62pg/ml, p =0.049), significantly lower Dkk-1 (1228 vs 3052pg/ml, p =0.001), but similar levels of SOST (369 vs 544pg/ml, p =0.144) compared to controls. Anti-TNF treatment did not affect GM-CSF, Dkk-1, or SOST levels. Spearman correlation analysis showed that GM-CSF correlated positively with ASDAS at baseline ( r =0.61, p =0.039), while no correlations were identified between bone markers (Dkk-1, SOST) on one hand and GM-CSF or disease activity indices on the other. Conclusions GM-CSF is increased in patients with active AS and strongly correlates with disease activity. TNF inhibition does not affect GM-SCF levels, despite improving disease activity. GM-CSF may represent an important pathway responsible for residual inflammation during TNF blockade, but also a potential target of JAK inhibitors, explaining their efficacy in r-axSpA." @default.
• W4291939922 created "2022-08-16" @default.
• W4291939922 creator A5008658097 @default.
• W4291939922 creator A5012743116 @default.
• W4291939922 creator A5020014399 @default.
• W4291939922 creator A5064220409 @default.
• W4291939922 creator A5088141005 @default.
• W4291939922 date "2022-08-16" @default.
• W4291939922 modified "2023-10-17" @default.
• W4291939922 title "Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment" @default.
• W4291939922 cites W1974619242 @default.
• W4291939922 cites W2028914771 @default.
• W4291939922 cites W2054797852 @default.
• W4291939922 cites W2097896494 @default.
• W4291939922 cites W2121330374 @default.
• W4291939922 cites W2474510828 @default.
• W4291939922 cites W2762791464 @default.
• W4291939922 cites W2953889774 @default.
• W4291939922 cites W2999595676 @default.
• W4291939922 cites W3016783094 @default.
• W4291939922 cites W3017277221 @default.
• W4291939922 cites W3114286944 @default.
• W4291939922 cites W3200290972 @default.
• W4291939922 cites W3214034736 @default.
• W4291939922 cites W4200267842 @default.
• W4291939922 cites W4200334918 @default.
• W4291939922 cites W4206565620 @default.
• W4291939922 doi "https://doi.org/10.1186/s13075-022-02888-6" @default.
• W4291939922 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35974380" @default.
• W4291939922 hasPublicationYear "2022" @default.
• W4291939922 type Work @default.
• W4291939922 citedByCount "6" @default.
• W4291939922 countsByYear W42919399222023 @default.
• W4291939922 crossrefType "journal-article" @default.
• W4291939922 hasAuthorship W4291939922A5008658097 @default.
• W4291939922 hasAuthorship W4291939922A5012743116 @default.
• W4291939922 hasAuthorship W4291939922A5020014399 @default.
• W4291939922 hasAuthorship W4291939922A5064220409 @default.
• W4291939922 hasAuthorship W4291939922A5088141005 @default.
• W4291939922 hasBestOaLocation W42919399221 @default.
• W4291939922 hasConcept C104317684 @default.
• W4291939922 hasConcept C109159458 @default.
• W4291939922 hasConcept C126322002 @default.
• W4291939922 hasConcept C137620995 @default.
• W4291939922 hasConcept C17991360 @default.
• W4291939922 hasConcept C185592680 @default.
• W4291939922 hasConcept C198451711 @default.
• W4291939922 hasConcept C202751555 @default.
• W4291939922 hasConcept C203014093 @default.
• W4291939922 hasConcept C2776213234 @default.
• W4291939922 hasConcept C2776260265 @default.
• W4291939922 hasConcept C2776694085 @default.
• W4291939922 hasConcept C2777402515 @default.
• W4291939922 hasConcept C2777453003 @default.
• W4291939922 hasConcept C2777478134 @default.
• W4291939922 hasConcept C2777767877 @default.
• W4291939922 hasConcept C2778579456 @default.
• W4291939922 hasConcept C2778690821 @default.
• W4291939922 hasConcept C2779134260 @default.
• W4291939922 hasConcept C2779244956 @default.
• W4291939922 hasConcept C2779277721 @default.
• W4291939922 hasConcept C28328180 @default.
• W4291939922 hasConcept C50442881 @default.
• W4291939922 hasConcept C54355233 @default.
• W4291939922 hasConcept C55493867 @default.
• W4291939922 hasConcept C71924100 @default.
• W4291939922 hasConcept C86803240 @default.
• W4291939922 hasConcept C880424 @default.
• W4291939922 hasConcept C90924648 @default.
• W4291939922 hasConceptScore W4291939922C104317684 @default.
• W4291939922 hasConceptScore W4291939922C109159458 @default.
• W4291939922 hasConceptScore W4291939922C126322002 @default.
• W4291939922 hasConceptScore W4291939922C137620995 @default.
• W4291939922 hasConceptScore W4291939922C17991360 @default.
• W4291939922 hasConceptScore W4291939922C185592680 @default.
• W4291939922 hasConceptScore W4291939922C198451711 @default.
• W4291939922 hasConceptScore W4291939922C202751555 @default.
• W4291939922 hasConceptScore W4291939922C203014093 @default.
• W4291939922 hasConceptScore W4291939922C2776213234 @default.
• W4291939922 hasConceptScore W4291939922C2776260265 @default.
• W4291939922 hasConceptScore W4291939922C2776694085 @default.
• W4291939922 hasConceptScore W4291939922C2777402515 @default.
• W4291939922 hasConceptScore W4291939922C2777453003 @default.
• W4291939922 hasConceptScore W4291939922C2777478134 @default.
• W4291939922 hasConceptScore W4291939922C2777767877 @default.
• W4291939922 hasConceptScore W4291939922C2778579456 @default.
• W4291939922 hasConceptScore W4291939922C2778690821 @default.
• W4291939922 hasConceptScore W4291939922C2779134260 @default.
• W4291939922 hasConceptScore W4291939922C2779244956 @default.
• W4291939922 hasConceptScore W4291939922C2779277721 @default.
• W4291939922 hasConceptScore W4291939922C28328180 @default.
• W4291939922 hasConceptScore W4291939922C50442881 @default.
• W4291939922 hasConceptScore W4291939922C54355233 @default.
• W4291939922 hasConceptScore W4291939922C55493867 @default.
• W4291939922 hasConceptScore W4291939922C71924100 @default.
• W4291939922 hasConceptScore W4291939922C86803240 @default.
• W4291939922 hasConceptScore W4291939922C880424 @default.
• W4291939922 hasConceptScore W4291939922C90924648 @default.
• W4291939922 hasFunder F4320323715 @default.
• W4291939922 hasIssue "1" @default.

• next